Acute Myelogenous Leukemia (AML) News

Leukemia May Shrivel If Fat Cells in Marrow Are Plumped - Genetic Engineering & Biotechnology News



Genetic Engineering & Biotechnology News
 
Leukemia May Shrivel If Fat Cells in Marrow Are Plumped 
Genetic Engineering & Biotechnology News
Altering the bone marrow environment so that it favors the formation of healthy blood cells and disfavors the formation of leukemic cells could present an indirect way to treat acute myeloid leukemia (AML). Indirect treatment options would be welcome ...

and more » 


Johnson & Johnson drops sirukumab after FDA blow, cans phase 3 AML trial - FierceBiotech



FierceBiotech
 
Johnson & Johnson drops sirukumab after FDA blow, cans phase 3 AML trial 
FierceBiotech
Today, J&J abandoned plans to win approval of its once-hyped rheumatoid arthritis drug sirukumab and stopped a phase 3 trial of talacotuzumab in acute myeloid leukemia (AML). The likelihood of J&J washing its hands of sirukumab jumped late last month ...
J&J Halts Sirukumab Development, Talacotuzumab Trial Genetic Engineering & Biotechnology News

all 9 news articles » 


Novartis drug RydaptŪ (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia ... - GlobeNewswire (press release)



pharmaphorum
 
Novartis drug RydaptŪ (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia ... 
GlobeNewswire (press release)
... induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adults with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive.
Novartis's Rydapt wins EU approval for AML, other diseases Reuters
EU green light for Novartis' Rydapt PharmaTimes
Novartis wins EU approval for leukemia drug Stock Market Wire

all 7 news articles » 


ImmunoGen to Push Leukemia Candidate into Phase I Trial - Zacks.com



ImmunoGen to Push Leukemia Candidate into Phase I Trial 
Zacks.com
... of its investigational new drug (IND) application for IMGN632, filed in mid-September for treating patients with CD123-positive hematological malignancies, including acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).

 


Cabozantinib May Be Effective for Acute Myeloid Leukemia - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Cabozantinib May Be Effective for Acute Myeloid Leukemia 
Cancer Therapy Advisor
Cabozantinib may help to evade drug resistance in patients with acute myeloid leukemia (AML), according to research published in Cancer.1. Standard cytotoxic chemotherapy remains the standard treatment for AML, though a large proportion of patients ...

 


Leukemia: Cancer cells killed off with diabetes drug - Medical News Today



Medical News Today
 
Leukemia: Cancer cells killed off with diabetes drug 
Medical News Today
"The standard-of-care for this disease hasn't changed in several decades." The American Cancer Society (ACS) estimate that 21,380 people will be diagnosed with acute myeloid leukemia (AML) in 2017. Most of these will be adults, as AML tends to target ...

and more » 


Actinium Pharmaceuticals Provides Update on Actimab-A Phase 2 ... - GlobeNewswire (press release)



Actinium Pharmaceuticals Provides Update on Actimab-A Phase 2 ... 
GlobeNewswire (press release)
NEW YORK, Oct. 04, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a biopharmaceutical ...
Actinium advancing mid-stage study of leukemia med Actimab-A; shares ahead 10% premarket Seeking Alpha

all 3 news articles » 


New hope for leukaemia treatment - Cosmos (blog)



Cosmos (blog)
 
New hope for leukaemia treatment 
Cosmos (blog)
Research published in the journal Nature Cell Biology this week could pave the way for a novel drug treatment against the devastating blood and bone marrow cancer acute myeloid leukaemia (AML). The disease, which killed over 900 Australians in 2014, ...

 


FDA Grants Orphan Drug Designation to Trovagene's PLK1 Inhibitor ... - PR Newswire (press release)



Rare Disease Report
 
FDA Grants Orphan Drug Designation to Trovagene's PLK1 Inhibitor ... 
PR Newswire (press release)
SAN DIEGO, Oct. 9, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that the U.S. ...
FDA grants orphan drug designation to PCM-075 for acute myeloid ... Healio
Trovagene Gets FDA Orphan Drug Designation for AML Treatment Rare Disease Report
Trovagene (TROV) PLK1 Inhibitor, PCM-075, Granted FDA Orphan ... StreetInsider.com
Stock News Union (blog)  -Smarter Analyst  -CNA Finance (press release) 
all 7 news articles » 


FDA Grants Gilteritinib Fast Track Designation for AML - OncLive



OncLive
 
FDA Grants Gilteritinib Fast Track Designation for AML 
OncLive
Gilteritinib is an investigational compound that has demonstrated inhibitory activity against FLT3 internal tandem duplication as well as FLT3 tyrosine kinase domain, two common types of FLT3 mutations present in approximately 1/3 of patients with AML.
FDA Fast Tracks Astellas' AML Treatment Rare Disease Report
FDA Grants Gilteritinib Fast Track Designation for FLT3-positive AML Cancer Therapy Advisor
CRY Opens Wallet, LLY's JUNIPER Flops, MDXG Catches Eyes, RNN Awaits DATA In Q4 Markets Insider
Seeking Alpha  -Healio  -GuruFocus.com 
all 8 news articles »